

# Biomarkers Role in Breast Cancer Treatment-A Review

Sakshi Tripathi\* and Aayush Madan

Department of Biotechnology Graphic Era University, Dehradun, India

## Review Article

Received: 10/12/2016  
Revised: 15/12/2016  
Accepted: 20/01/2017

### \*For Correspondence

Sakshi Tripathi, Department of  
Biotechnology, Graphic Era  
University, Clement Town,  
Dehradun, India Tel:  
+919455301034

E-mail: [sakshi21.t@gmail.com](mailto:sakshi21.t@gmail.com)

**Keywords:** Breast Cancer,  
Chemotherapy, Metastatic,  
Radiotherapy, Breast

## ABSTRACT

Cancer begins as a nearby sickness, yet it can metastasize to the lymph hubs and far off organs. At essential finding, prognostic markers are utilized to survey whether the move to systemic illness is probably going to have happened. The overall model of metastasis mirrors this view - it recommends that metastatic limit is a late, obtained occasion in tumourigenesis. Others have proposed the possibility that breast tumour is inherently a systemic sickness. New atomic advancements, for example, DNA microarrays, bolster metastatic limit may be an innate component of breast tumours. This information has critical ramifications for visualization prediction and our comprehension of metastasis.

## INTRODUCTION

**Breast cancer** is the most widely recognized harmful disease in Western women. In these patients, it is not the essential tumour, but rather its metastases at far off locales that are the fundamental driver of death. As of late, the rates of metastasis and mortality in breast **malignancy** patients have diminished as an after effect of early <sup>[1-5]</sup> determination by mammographic screening and the usage of systemic adjuvant therapy. Adjuvant treatment can annihilate breast tumour cells that may have effectively spread too far off locales when of analysis. In women with breast <sup>[6-10]</sup> growth who are more youthful than 50 years old, chemotherapy builds their 15-year survival rate by 10%; in more seasoned women the expansion is 3%. Nonetheless, **chemotherapy** has an extensive variety of intense and long haul symptoms that significantly influence the patient's nature of life. As it is unrealistic to precisely foresee <sup>[11-15]</sup> the danger of metastasis advancement in individual patients, these days more than 80% of them get adjuvant chemotherapy, albeit just <sup>[15-20]</sup> roughly 40% of the patients backslide and at last bite the dust of **metastatic** breast tumour. Along these lines, numerous women who might be cured by nearby treatment alone, which incorporates surgery and **radiotherapy**, will be over-treated and endure the lethal reactions of <sup>[20-26]</sup> chemotherapy unnecessarily. So there exists a need to be aware of the breast cancer risks and symptoms so that its prevention and cure <sup>[28-32]</sup> are possible in a right way. People can get to know about this through literature, internet sources, family physicians and consultants. **Open access journals** provide more visibility and accessibility to the readers in gaining the required information. The on-going researches all over the world, which are being exhibited through open access journals, serve as the main source of information in various fields.

In order to impart knowledge and create awareness among the people, group of physicians and consultants unite to form a **society** or an organization. The main aim of these societies is to counsel and create awareness among the

victims of [breast](#) cancer as well as healthy personnel [33-37]. Major societies like [Senologic International Society](#) aims on bringing together the national societies of Senology around the world and improving the knowledge and quality of breast health assistance worldwide. [European Society of Oncology Pharmacy](#) aims to support optimal [treatment](#) for cancer patients, to develop and promote clinical and oncology [38-40] pharmacy practice through education and training, safe handling and administration of drugs, quality management, research and development and pharmaceutical care. It also aims to make information on knowledge and achievements in cancer treatment and activities [41-45] available to the public and also to spread the information by publications, professional activities as well as educational lectures and seminars. [Lebanese Society of Obstetrics & Gynecology](#) promotes scientific knowledge [46,47] on gynaecology related diseases like breast cancer its treatment and cure. [European Biotechnology Thematic Network Association](#) (EBTNA) aims to establish new techniques [48-50] which can help in prevention and cure of various diseases like cancer etc.

Open Access literature plays a key role in proving the information and [50-55] current researches across the globe. [Journal of Cancer Science & Therapy](#) provides information on various [57-60] types of cancer and its treatments. [Journal of Clinical and Experimental Oncology](#) imparts knowledge on latest therapeutics techniques such as radiotherapy, Cancer Gene Therapy, [Tumour](#) Therapy and Oncologic Surgery and also many conferences [61,62] like International Conference on Oncology Nursing, Cancer Care & Radiology and Imaging was conducted where an abstract entitled Volumetric, molecular and image guidance [63-65] for radiotherapy of cancer illustrated by Boguslaw Maciejewski showed the impact and significance of initial tumour volume (ITV) vs. TNM staging on radiotherapy outcome (3 yrs. LRC) and application of [65-70] molecular and radiological images for personalized optimization of radiotherapy. [Andrology and Gynecology : Current Research](#) is an international [peer-reviewed scholarly journal](#), which publishes papers across the world on various [gynecologic](#) issues such as ovarian cancer, breast cancer, cervical cancer, ectopic pregnancy, in vitro fertilization etc. [Journal of Carcinogenesis & Mutagenesis](#) aims to improve [71,72] the knowledge and provide cutting-edge research strategies for the development of new therapeutics. The above mentioned Open access journals related to breast cancer [73-75] are the peer-reviewed journals that maintain the quality and standard of the journal content, reviewer's agreement and respective editor's acceptance in order to publish an article. These journals ensures the [76] barrier-free distribution of its content through online open access and thus helps in improving the citations for authors and attaining good journal impact factors.

## BIOMARKERS ROLE IN DETECTING CANCER

### Prognostic Markers

New [prognostic markers](#) earnestly expected to recognize patients who [77,78] are at the most astounding danger for creating metastases, which may empower oncologists to start fitting treatment procedures to individual patients. Topics related to **Gynecologic Oncology: Symptoms** were discussed in [Experts Meeting on Gynecologic Oncology](#) held on May 19-21, 2016 at San Antonio, Texas, USA. Quality expression marks of [79,80] essential breast tumours may be one approach to recognize the patients who are well on the way to create metastatic disease, and would thusly profit by adjuvant treatment. Moreover, quality expression profiling of bosom tumours may likewise recognize new remedial targets.

Giles S L Davies discussed about Defining the association and potential role of human papillomavirus and breast cancer in [2nd Gynecologic Cancer Conference](#) held on Oct 17-18, 2016 in Rome, Italy.

### Established Prognostic Markers

The danger of metastasis advancement increments <sup>[81-85]</sup> with the nearness of lymph-hub metastasis, a bigger estimated essential tumour and loss of histopathological separation (grade) which are the set up bosom disease prognostic markers. Topics like <sup>[86-88]</sup> cancer biomarkers and molecular biomarkers are going to be discussed in [9th International Conference and Expo on Molecular & Cancer Biomarkers](#) which is going to be held on August 24-25, 2017 in Birmingham, UK. Topics like breast cancer are going to be discussed in [2nd International Congress on Contemporary Issues in Women Cancers and Gynecologic Oncology](#) which will be held in August, 2017 London, UK. Today, the conventional <sup>[89-92]</sup> prognostic markers can unquestionably distinguish the gathering of roughly 30% of patients, who are well on the way to have either an exceptionally positive or an extremely poor result. Topics related to breast cancer [therapy](#), management and prevention are going to be discussed in the upcoming [5th World Congress on Breast Cancer](#) .

For the staying 70% of patients, of whom around 30% will in any case <sup>[93-97]</sup> create metastases, new prognostic markers are expected to distinguish generally safe and high-hazard gatherings to pinpoint those patients who are destined to profit by systemic adjuvant treatment.

### Recent Prognostic Markers

Generous endeavours have been <sup>[98-102]</sup> made to distinguish extra prognostic markers that portray patients with bosom tumour who are at the most noteworthy danger of metastasis advancement. Topics like preventive oncology are going to be discussed in [World Congress on Preventive Oncology](#) in July 2017 Chicago, Illinois, USA. To meet <sup>[103-106]</sup> the prerequisites of a prognostic marker, the potential marker ought to be tried reflectively in vast patient associates with a long follow-up period. Multivariate Analysis <sup>[107-110]</sup> should be done in conjunction with set up markers to evaluate its autonomous esteem. Topics related to Gynecological Oncology were discussed in [3rd International Conference on Gynecology & Obstetrics](#) held on November 24-26, 2016 in Dubai, UAE. Along these lines, the discoveries ought to be approved by an autonomous gathering of analysts, and, in a perfect world, a prospective study ought to affirm <sup>[111-115]</sup> the prognostic noteworthiness of the tried marker. [Scott D. Richard](#) a scientific professional has research expertise in Cancer Hereditary, Colorectal Cancer, Ovarian Cancer and various other types of cancer.

**ERBB2.** Among numerous [biomarkers](#) epidermal growth <sup>[116-118]</sup> consider receptor 2 (ERBB2; otherwise called HER2/neu) has raised much consideration as a conceivable prognostic marker. The human ERBB2 proto-oncogene encodes a transmembrane receptor with constitutive tyrosine-kinase movement. ERBB2 is overexpressed because of quality <sup>[119]</sup> intensification in 15-30% of human breast cancers. The prognostic estimation of ERBB2 was initially guaranteed in 1987, and from that point on it has been broadly considered. Topics like Cancer Cell Biology <sup>[120-122]</sup> are going to be discussed in [Global Summit on Oncology & Cancer](#) May, 2017 Osaka, Japan. The ERBB2 status of breast tumours has increased clinical importance because of the presentation of trastuzumab, a remedial monoclonal immune response that is coordinated <sup>[123]</sup> against the receptor, and which drags out survival in patients with metastatic bosom cancer. Topics like Cancer Treatments and Therapies are going to be discussed in [2nd Cancer Diagnostics Conference & Expo](#) in May, 2017 Barcelona, Spain. In addition, expanding proof <sup>[124-127]</sup> likewise demonstrated that ERBB2 may be a predictive marker for reaction to adjuvant chemotherapy and endocrine treatment. This may clarify why the testing of recently analyzed breast malignancy examples for ERBB2 status has accomplished 'standard of practice' status for the <sup>[128-130]</sup> administration of breast disease. This is in spite of the

prognostic estimation of ERBB2 for sickness free and general survival in patients with lymph-hub positive bosom growth being determined as powerless <sup>[131-133]</sup> to-direct by the World Health Organization Classification of Tumours. Plainly, extra all around controlled and all around outlined reviews with adequate follow-up time must be led to enough approve the prognostic essentialness of ERBB2.

### DETECTION OF DISSEMINATED TUMOUR CELLS

To build up a metastasis, tumour cells need to attack <sup>[134-136]</sup> their encompassing host tissue, enter the circulatory circulation system, capture in narrow beds of far off organs, attack the host tissue and multiply. [Kurt S Zaenker](#) is a scientific professional with expertise in migration machinery of cancer cells. As little tumours of under 2 mm in breadth as of now get a vascular blood supply, it is likely that malignancy cells have spread all through the body years <sup>[137-140]</sup> before they are initially recognized. [Thomas J. Rutherford](#) is a scientific professional with research expertise in stem cell research and early cancer detection. The advancement of a measure to identify these cells before the indication of far off metastases may in this way is <sup>[141-145]</sup> helpful for patient guess. The look for coursing tumour cells began in the late 1980s, and today both immunohistochemical recoloring and PCR-based methodologies <sup>[146-150]</sup> are accessible to recognize scattered tumour cells. Dr. [David Mutch](#) is a scientific professional who has research expertise in gynecologic oncology, endometrial cancer, vulva carcinoma, ovarian cancer, cervical cancer. [Lwaleed Bashir Abdulgader](#) is a scientific professional and has research expertise in <sup>[151]</sup> Haemostasis and Cancer Therapy. These strategies depend on the nearness of bosom epithelial markers, in fringe blood, bone marrow and lymph hubs.

Attributable to specialized issues with respect to <sup>[152,153]</sup> the uncommonness of the dispersed cells and the foundation expression levels of these markers, just a couple contemplates have been distributed that inspect the relationship between the nearness of coursing <sup>[154-156]</sup> tumour cells in fringe blood and patient result. [Fred M Moeslein](#) is a scientific professional has research expertise in Selective Internal Radiotherapy. Two clinical reviews demonstrated that the scattered tumour-cell stack in fringe blood is connected with abbreviated sickness free interims and decreased general survival in patients with early breast cancer.

### CONCLUSION

New prognostic markers of [breast tumour](#) metastasis are earnestly expected to keep away from overtreatment or under treatment of recently analysed patients. Microarray quality expression examination has demonstrated guarantee as a helpful prognostic marker. Be that as it may, do these reviews furnish us with new tumour markers that can be routinely utilized for recently analysed breast disease patients? Obviously, to permit microarray testing in all healing facilities, the innovation and access to it should be made strides. Besides, the present framework to get these quality expression marks to the most abnormal amount of clinical use requires substantial planned randomized trials. It is trusted that the present medicinal services framework can't take the budgetary weight to test all new tumour markers along these lines. Then again, in light of the immense prescient force of quality expression marks, a few very much outlined review studies may be adequate for their presentation into the centre. Quality expression marks may likewise be utilized to anticipate the site of human tumour [metastasis](#) these can right now be anticipated in mice. The distinguishing proof of tissue-particular marks for metastasis would not just enhance our comprehension of the components by which tumours spread to particular tissues, however would likewise recognize new restorative targets. What's more, we anticipate the ID of prescient quality expression profiles that will empower us to tailor adjuvant treatment decisions to people. It has also been so far reported the

relationship between a quality expression mark and medication affectability to docetaxel or to a mix regimen containing paclitaxel, fluorouracil, doxorubicin and cyclophosphamide in breast tumour patients.

## REFERENCES

1. Khedr RAE and Ghannam AAE. A Clinical Phase II Study of Oral Vinorelbine in HER-2 Negative Metastatic Breast Cancer. *J Cancer Sci Ther.* 2016;8:262-267.
2. Lai Y and Lai J. Severe Liver Toxicity in a Lung Cancer Patient Treated with Erlotinib A Case Report and Literature Review. *J Cancer Sci Ther.* 2016;8:268-273.
3. Zhang H, et al. Effect of Sevoflurane Preconditioning on Inflammatory Cytokines and Oxygen Radicals During Single Lung Ventilation in Patients with Lung Cancer. *J Cancer Sci Ther.* 2016;8:274-276.
4. Chengo JK, et al. Antiproliferative Activity of Kenyan *Trametes versicolor* Aqueous Extract on Selected Cancer and Normal Cell Lines. *J Cancer Sci Ther.* 2016;8:277-281.
5. Sinha BK. Nitric Oxide: Friend or Foe in Cancer Chemotherapy and Drug Resistance: A Perspective. *J Cancer Sci Ther.* 2016;8:244-251.
6. Baram A and Tayeb ZA. Mediastinal Masses: Retrospective Single Center Based Study. *J Cancer Sci Ther.* 2016;8:252-256.
7. Rihan FA and Rihan NF. Dynamics of Cancer-Immune System with External Treatment and Optimal Control. *J Cancer Sci Ther.* 2016;8:257-261.
8. Alexandrova E, et al. Breast-Conserving Therapy Versus Radical Mastectomy for Early Breast Cancer: 20 Year Follow Up. *J Cancer Sci Ther.* 2016;8:228-232.
9. Radzikowska E, et al. Lymphangioma in Patients with Pulmonary Lymphangiomyomatosis Results of Sirolimus Treatment. *J Cancer Sci Ther.* 2016;8:233-239.
10. Sur D and Chakravorty R. Present Status of Cervical Neoplasia Control and Human Papilloma Virus Epidemiology in India The Wind is Blowing Unfolding the Truth. *J Cancer Sci Ther.* 2016;8:240-243.
11. Shankar A, et al. Anti-VEGFR2 Driven Nuclear Translocation of VEGFR2 and Acquired Malignant Hallmarks are Mutation Dependent in Glioblastoma. *J Cancer Sci Ther.* 2016;8:172-178.
12. Loh SY and Jonsson H. Cancer Survivorship Care: A perspective from an Occupational-Participation Approach. *J Cancer Sci Ther.* 2016;8:179-184.
13. Zhang D, et al. Prognostic Value of Lymph Node Number and Ratio Staging System in Stage III Rectal Cancer Following Neoadjuvant Radiochemotherapy. *J Cancer Sci Ther.* 2016;8:185-189.
14. Khalid A and Javaid MA. Fibroblast Growth Factors and their Emerging Cancer-Related Aspects. *J Cancer Sci Ther.* 2016;8:190-205.
15. Khedr RAE, et al. The Prognostic Role of Tumor-Infiltrating Lymphocytes CD8 and Foxp3 and their Impact on Recurrence in Breast Cancer Patients. *J Cancer Sci Ther.* 2016;8:206-212.
16. Bisen PS. Nutritional Therapy as a Potent Alternate to Chemotherapy against Cancer. *J Cancer Sci Ther.* 2016;8:e135.
17. Khalid A and Javaid MA. Matrix Metalloproteinases: New Targets in Cancer Therapy. *J Cancer Sci Ther.* 2016;8:143-153.

18. Geleta B, et al. N-myc Downstream Regulated Gene (NDRG) Role in Cancer Metastasis Suppression and as Drug Target in Cancer Therapeutics. *J Cancer Sci Ther.* 2016;8:154-159.
19. Geleta B, et al. Cyclic Dependent Kinase (CDK) Role in Cancer Pathogenesis and as Drug Target in Cancer Therapeutics. *J Cancer Sci Ther.* 2016;8:160-167.
20. Murugan NJ, et al. Differentiation of Malignant Compared to Non-Malignant Cells by Their Bio- Photon Emissions May Only Require a Specific Filter around 500 nm. *J Cancer Sci Ther.* 2016;8:168-169.
21. Brafford P, Sproesser K, Krepler C, Herlyn M (2016) 1205Lu is Human Melanoma Depending on the Source. *J Cancer Sci Ther* 8:113.
22. Njagi SM, et al. *In Vitro* Antiproliferative Activity of Aqueous Root Bark Extract of *Cassia abbreviata* Holmes Brenan. *J Cancer Sci Ther.* 2016;8:114-121.
23. Ahmad A, et al. PIK3CA and EGFR Gene Mutations are Associated with Lymph Node Metastasis and Right Sided Colon Carcinoma. *J Cancer Sci Ther.* 2016;8:122-129.
24. Nyamai DW, et al. Herbal Management of Benign Prostatic Hyperplasia. *J Cancer Sci Ther.* 2016;8:130-134.
25. Ahmad F, et al. CD24 Induces the Activation of  $\beta$ -Catenin in Intestinal Tumorigenesis. *J Cancer Sci Ther* 2016;8:135-142.
26. Barik S. Combination Therapy for Chronic Lymphoid Leukemia. *J Cancer Sci Ther.* 2016;8:078-079.
27. Maździarz A, et al. Benign Metastasizing Leiomyomas of the Lungs A Case Report. *J Cancer Sci Ther.* 2016; 8:080-083.
28. Stramare R, et al. Imaging Features, Differential Diagnosis and Management of Leiomyosarcomas Case Series and Review of the Literature. *J Cancer Sci Ther.* 2016;8:084-091.
29. Álvarez-Bañuelos MT, et al. Prognostic Factors Associated with Survival in Women with Breast Cancer from Veracruz, Mexico. *J Cancer Sci Ther.* 2016;8:092-098.
30. Gayatri Devi V, et al. Therapeutic Potentials of CD151 shRNA in Targeting Metastasis of Triple Negative Breast Cancer Cell Line MDA-MB-231. *J Cancer Sci Ther.* 2016;8:104-112.
31. Tot T and Gere M. Radiologically Unifocal Invasive Breast Carcinomas: Large-Section Histopathology Correlate and Impact on Surgical Management. *J Cancer Sci Ther.* 2016;8:050-054.
32. Reyad D, et al. Hyponatremia and SIADH Frequency in Clinically Euvolemic Patients Receiving Chemotherapy Prospective Study in Unselected Patients' Cohort. *J Cancer Sci Ther.* 2016;8:055-058.
33. Ofor O, et al. CTCF May Not Directly Regulate ER $\alpha$  mRNA Expression in the ER+ MCF7 Breast Cancer Cell Line. *J Cancer Sci Ther.* 2016;8:059-065.
34. García-Novoa A and Acea-Nebriil B. Controversies in Axillary Treatment of Breast Cancer Patients and Metastatic Sentinel Lymph Node. *J Cancer Sci Ther.* 2016;8:066-068.
35. Paul I and Ghosh MK. Chaperones and Glioma Immunotherapy. *J Cancer Sci Ther.* 2016;8:069-070.
36. Kamphuis GM, et al. Storz Professional Image Enhancement System A New Technique to Improve Endoscopic Bladder Imaging. *J Cancer Sci Ther.* 2016;8:071-077.
37. Cascales Campos PA, et al. Hipec in Ovarian Cancer. Why is it Still the Ugly Duckling of Intraperitoneal Therapy? *J Cancer Sci Ther.* 2016;08:030.
38. Doerner J, et al. Presentation of Gastric Adenocarcinoma with Acute Arterial Occlusive Disease Nonbacterial Thrombotic Endocarditis and Pyogenic Liver Abscess. *J Cancer Sci Ther.* 2016;8:031-035.

39. Ganapathy-Kanniappan S. Selective Inhibition of Lactate Influx in Cancer An Opportunity to Augment Therapeutic Targeting. *J Cancer Sci Ther.* 2016;8:036-037.
40. Dadlani K, et al. Assessment of the Expression of Long Noncoding Mitochondrial RNAs (lncmtRNAs) During Cervical Cancer Progression and Cervical Carcinoma. *J Cancer Sci Ther.* 2016;8:038-045.
41. de Farias CB, et al. Resistance to Anti- EGFR Therapy and Strategies to Overcome it Possible Role of BDNF/TrkB. *J Cancer Sci Ther.* 2016;8:046-047.
42. Santosh T, et al. Nodular Hidradenoma: A Rare Cytological Diagnosis. *J Cancer Sci Ther.* 2016;8:048-049.
43. Walker AM, et al. Evaluation of Arsenic Trioxide Potential for Lung Cancer Treatment Assessment of Apoptotic Mechanisms and Oxidative Damage. *J Cancer Sci Ther.* 2015;8:001-009.
44. Chandel SS and Jain RK. Evaluation of Role of Concurrent Chemotherapy and Brachytherapy in Locally Advanced Cervical Cancer Patients. *J Cancer Sci Ther.* 2016;8:010-014.
45. den Bergh JMJV, et al. Interleukin-15 and Interleukin-15 Receptor  $\alpha$  mRNA-Engineered Dendritic Cells as Promising Candidates for Dendritic Cell-Based Vaccination in Cancer Immunotherapy. *J Cancer Sci Ther.* 2016;8:015-019.
46. Akhenblit PJ and Pagel MD. Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy. *J Cancer Sci Ther.* 2016;8:020-029.
47. Sauer MV. Egg Banks: Moving the Concept from Wishful Thinking to Clinical Reality. *Androl Gynecol: Curr Res.* 2012;1:1
48. Varras M. The Expression of Genes in Human Ovarian Granulosa Cells during Assisted Reproduction Technologies and their Clinical Significance. *Androl Gynecol: Curr Res.* 2012;1:1
49. Shah C, et al. Breast Cancer Related Lymphedema: A Review of Recent Developments. *Androl Gynecol: Curr Res.* 2013;1:2.
50. Kort DH, et al. Finding Fibers: Intrauterine Synechia of the Lower Uterus after Cesarean Section. *Androl Gynecol: Curr Res.* 2013;1:2.
51. Moparty K. Is there a True Link between HCV and Pathogenesis of RCC? *Androl Gynecol: Curr Res.* 2013; 1:2.
52. Favero G, et al. Spontaneous Resolution of an Iatrogenic Ureterovaginal Fistula after Clinical Treatment of Hypothyroidism: A Case Study with a Review of the Literature. *Androl Gynecol: Curr Res.* 2013;1:2.
53. Suresh PS, et al. Molecular Pathology and Therapy of Endometriosis: Revisited. *Androl Gynecol: Curr Res.* 2013;1:3.
54. Chakrabarty A. Recent Advances in Hypogonadism. *Androl Gynecol: Curr Res.* 2013;1:3.
55. Alipour S and Eskandari A. Perspectives of Maternity after Breast Cancer. *Androl Gynecol: Curr Res.* 2013; 2:1.
56. Raheem AA, et al. MiniArc® Sling for the Treatment of Female Stress Urinary Incontinence. *Androl Gynecol: Curr Res.* 2013;2:1.
57. Heaton RL and Walid MS. Examination under Anesthesia: An Invaluable Tool for Localizing Retroperitoneal Tumors. *Androl Gynecol: Curr Res.* 2013;2:1.
58. Mahendru R, et al. Anti-Oxidant Intake in Antenatal Cases High-Risk for Pregnancy Induced Hypertension and Intrauterine Growth Restriction. *Androl Gynecol: Curr Res.* 2013;2:1.

59. Bousquet G and Janin A. Can Cancer Brain Metastases be Treated Using Humanized Monoclonal Antibodies? *Chemotherapy*. 2015;4:e127.
60. Young-Soo Lee, et al. Synergistic Effect between Baicalein and Antibiotics against Clinic Methicillin and Vancomycin-Resistant *Staphylococcus aureus*. *Chemotherapy*. 2015;3:141.
61. Mohamed Hassan, et al. Ubiquitin Proteasome System as Target for Tumor Therapy. *Chemo Open Access*. 2015;4:142.
62. Mark F Mc Carty. Tumor-Specific Induction of Oxidative Stress with Dichloroacetate and Auranofin May Complement the Efficacy of PARP Inhibition in Cancer Control. *Chemo Open Access*. 2015;4:143.
63. Sugiura H, et al. Therapeutic Efficacy and Dosage of Pazopanib for Metastatic or Unresectable Advanced Soft Tissue Sarcomas. *Chemotherapy*. 2015;4:144.
64. Taira N, et al. The Effectiveness and Tolerance of TS-1 a Monotherapy for Relapsed Thymic Cancer Patient Who could not Tolerate Platinum Compounds. *Chemotherapy*. 2015;4:145.
65. Revathi B and Prashanth K. Potential Hsp90 Inhibitors: A Novel Target for Cancer Therapy. *Chemotherapy*. 2015;4:146.
66. Mukesh C Sharma. QSAR Analysis of 3- and 4-substituted 7-hydroxycoumarins as Novel 17 $\beta$ -HSD3 Inhibitors. *Chemotherapy*. 2015;4:148.
67. Renata MF Gomes, et.al. Potential Spread of Methicillin-Resistant *Staphylococcus aureus* Recovered from Patients with Bloodstream Infection. *Chemo Open Access*. 2015;4:149.
68. Agbessi O, et.al. Extended Arm Necrosis by Chemotherapy Drugs Extravasation. *Chemo Open Access*. 2015;4:147.
69. Zümürüt AKGÜN SAHİN and Seher ERGÜNEY. Determining Reactions and Anger Expressions of Family Members Giving Care for Receiving Chemotherapy. *Chemo Open Access*. 2015;4:150.
70. Costello LC, et al. Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach . *Chemotherapy*. 2015;4:152.
71. Chen J, et al. Recurrent Invasive Pulmonary Mucinous Adenocarcinoma Showing Responses to Platinum-Based Chemotherapy Regimens with Docetaxel and Bevacizumab:A Case Report . *Chemo Open Access*. 2015;4:151.
72. Pütz G. EPR-Effect and Nano-medicine Backdoor or Bottleneck?. *Chemo Open Access*. 2015;4:e128.
73. Landre Thierry. Maintenance Therapy after First Line Chemotherapy Shows Benefit in Advanced Non-Small Cell Lung Cancer. *Chemo Open Access*. 2015;4:153.
74. Caterina Soldà and Davide Pastorelli. Chemotherapy-Induced Nausea and Vomiting (CINV) the Achilles' Heel of Oncologists. *Chemo Open Access*. 2015;4:154.
75. Toshihiko Hirano. Polymethoxy Flavonoids: Possible Candidates for Overcoming Drug Resistance. *Chemo Open Access*. 2015;4:156.
76. Yano K , et al. Diverse Approval Systems for Autologous Human Cells and Tissue Products. *Chemo Open Access*. 2015;4:157.
77. Kolberg M, et al. Adjuvant Treatment For Patients With Malignant Peripheral Nerve Sheath Tumours. *Chemo Open Access*. 2015;4:158.
78. Swaika A, et al. Langerhans Cell Sarcoma: Treatment with Dose-adjusted EPOCH . *Chemo Open Access*. 2015;4:155.



79. Zhang P, et al. Clinicopathologic Characteristics and Multidisciplinary Treatment of Neuroendocrine Carcinoma of Gallbladder: Report of Three Cases with an Update. *Chemotherapy*. 2015;4:159.
80. Bardoscia L, et al. Pulmonary Epithelioid Hemangioendothelioma: Advances in Treatment Options despite a Rare Vascular Tumor. *Chemo Open Access*. 2015;4:160.
81. Nicholas OJ, et al. Neoadjuvant Therapy in Oesophageal Cancer- An International Standard of Care. *Chemo Open Access*. 2015;4:161.
82. Gattass CR. Exploring Melissa Officinalis Properties for Glioblastoma Multiforme Treatment. *Chemo Open Access*. 2015;4:162.
83. Baba Y and Yasumasa K. The Role of Bevacizumab in the Management of Head and Neck Squamous Cell Carcinoma Patients. *Chemo Open Access*. 2015;4:163.
84. Ribers JM. Blinatumomab: A Promising New Drug in the Therapeutic Armamentarium for Acute Lymphoblastic Leukemia. *Chemo Open Access*. 2015;4:164.
85. Maras B, et al. Resistance in *Candida albicans*: Exploring the Cell Wall Barrier by Proteomics. *Chemo Open Access*. 2015;4:165.
86. Genestreti G, et al. First-Line Platinum-Based Chemotherapy Re-challenge in Sensitive Small Cell Lung Cancer (SCLC): A Standard Treatment?. *Chemo Open Access*. 2015;4:166.
87. Williams CKO. High-Dose Cytosine Arabinoside Chemotherapy of Burkitt Lymphoma: Advocating Sustainable Strategies for Capacity Building in Systemic Cancer Care in Nigeria. *Chemo Open Access*. 2015;4:167.
88. Cohen MS. The Newest Targeted Therapeutics for Thyroid Cancer: Development of Sorafenib and Lenvatinib. *Chemo Open Access*. 2015;4:168.
89. Elzbieta Pels. Concentration of Tumour Necrosis Factor-Alpha in Saliva of Patients with Acute Lymphoblastic Leukaemia in Relation to Oral Mucositis during Chemotherapy. *Chemo Open Access*. 2015; 4:169.
90. Nadlaou B, et al. Prevalence Multi-Resistant Bacteria in Hospital N'djamena, Chad. *Chemo Open Access*. 2015;4:170.
91. Aktug H, et al. Investigation of the Cell Stabilization and the Epithelial to Mesenchymal Transition Effect of Flavopiridol in Mouse Lung Squamous Cell Carcinoma. *Chemo Open Access*. 2015;4:171.
92. Guiyong Peng. Effectiveness of Endoscopic Classification in Assessing Tumor Infiltration Depth and Capacity of Early Oesophageal Carcinoma. *Chemo Open Access*. 2015;4:173.
93. Itano O, et al. Oral Adjuvant Chemotherapy with S-1 or Uracil-tegafur versus Surgery Alone in Patients with Biliary Tract Cancer. *Chemo Open Access*. 2015;4:174.
94. Jyoti BS. Accuracy of MRI for Prediction of Response to Neo-Adjuvant Chemotherapy in Triple Negative Breast Cancer Compared to Other Molecular Types. *Chemo Open Access*. 2015;5:175.
95. Cheng Liu. Limb Salvage Strategy by Intra-Arterial Chemotherapy for Local Recurrent Osteosarcoma in Extremities. *Chemo Open Access*. 2015;5:176.
96. Christos K. Follow up of Testicular Tumours for How Long it is Necessary?. *Chemo Open Access*. 2015;5:177.
97. Sharma and Cheng. New & Emerging Drugs for Squamous Cell Lung Cancer. *Chemo Open Access*. 2015; 5:178.
98. De Domenico EBL, et al. Professional Competence in Oncology: Challenges for Education . *Chemo Open Access*. 2015;5:179.

99. Niang M, et al. Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-L-Carnitine in Mice with a Solid Form of Ehrlich Tumour. *Chemo Open Access*. 2015;5:180.
100. Soldà C, et al. Good and Prolonged Response to Low Dose Capecitabine as Second Line Therapy in a Patient with Advanced Hepatocellular Carcinoma. *Chemo Open Access*. 2015;5:181.
101. Xu M, et al. Aggressive Natural Killer Cell Leukemia Secondary to Hodgkin Lymphoma: a Case Report and Review of the Literature. *Chemo Open Access*. 2016;5:182.
102. Yasuhiro Kodera. A search for Optimal Cytotoxic Drug as a Partner for the Oral Fluoropyrimidines in the Postoperative Adjuvant Chemotherapy for Gastric Cancer. *Chemo Open Access*. 2016;5:183.
103. Provenzano M and Xavier Keller E. The Potential Therapeutic Usefulness of Targeting BK Polyomavirus in Prostate Cancer. *Chemo Open Access*. 2015;5:184.
104. Chen Y and Wan X. Lmdd-MPFG Prevents HCC Occurrence through Dendritic Cells Related Signaling Pathways. *Chemo Open Access*. 2016;5:185.
105. Wang YM, et al. A Study Design: Concurrent EGFR-TKI and Thoracic Radiotherapy as Firstline Treatment of Stage IV NSCLC Patients with EGFR Active Mutations (CERTAIN Study). *Chemo Open Access*. 2016;5:186.
106. Akihiko Osaki. Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy. *Chemo Open Access*. 2016;5:187.
107. Heidari A. A Chemotherapeutic and Biospectroscopic Investigation of the Interaction of Double-Standard DNA/RNA-Binding Molecules with Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh<sub>2</sub>O<sub>3</sub>) Nanoparticles as Anti-Cancer Drugs for Cancer Cells' Treatment. *Chemo Open Access*. 2016;5: e129.
108. Principe M, et al. Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic Cancer. *Chemo Open Access*. 2016;5:188.
109. Bagella L and Marchesi I. SFK Inhibitors as New Strategy for RMS Treatment. *Chemo Open Access*. 2016; 5:189.
110. Zhang M, et al. Targeting Human  $\beta$ -Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment. *Chemo Open Access*. 2016;5:190.
111. Di Agostino S and Blandino G. Genomic Instability: The Pivotal Role of Mutant p53 in Human Cancers. *Chemo Open Access*. 2016;5:191.
112. Wang Y, et al. Raltitrexed based Transcatheter Arterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma: A Single-center Randomized Controlled Study. *Chemo Open Access*. 2016; 5:192.
113. Cheng H, et al. A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient. *Chemo Open Access*. 2016;5:193.
114. Ullah E, et al. Prognostic Role of Microvascular Density and Mucin Production in 56 Cases of Adenocarcinoma of Lung- An Experience from a Center in Lahore, Pakistan. *Chemo Open Access*. 2016; 5:194.
115. Zhu M, et al. Alpha Fetoprotein Plays Antagonistic Role in Benzyl-Isothiocyanate Arresting Cell Cycle in Liver Cancer Cells. *Chemo Open Access*. 2016;5:195.
116. Lucibello M and De Braud F. Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer. *Chemo Open Access*. 2016;5:196.

117. Kubo A, et al. NK-1 Receptor Antagonists: Who Truly Need them and their Cost- Effectiveness Analysis?. Chemo Open Access. 2016;5:197.
118. Fedele M, et al. The Tumor Suppressive Role of PATZ1 in Thyroid Cancer: A Matter of Epithelial-Mesenchymal Transition. Chemo Open Access. 2016;5:198.
119. Dong J, et al. Targeting ROS for Cancer Therapy. Chemo Open Access. 2016;5: 199.
120. Yang H, et al. FBXW7 Pathway Functions as a Promising Therapeutic Target of Cholangiocarcinoma. Chemo Open Access. 2016;5:201.
121. Oh SD, et al. Hyaline-Vascular Variant Castleman Disease. Chemo Open Access. 2016;5:1101.
122. Bharath V and Hsia CC. Chronic Lymphocytic Leukemia with Leptomeningeal Involvement. Chemo Open Access. 2016;5:1102.
123. Yu G. Metformin as an Anticancer Drug: A Commentary on the Potential Therapeutic Strategy and Underlying Mechanism of Metformin in Gastric Cancer. Chemo Open Access. 2016;5:202.
124. Mukherjee R, et al. Current Understanding of Epidemiology, Genetic Etiology and Treatment of Gliomas from Indian Population. Chemo Open Access. 2016;5:203.
125. Rashid OM, et al. A Systematic Approach to Preclinical Trials in Metastatic Breast Cancer. Chemo Open Access. 2016;5:204.
126. Xu Y, et al. Interferon- $\gamma$  Upregulates SOCS3 Expression to Reduce Cisplatin Chemoresistance in Non-Small Cell Lung Cancer A549 Cells. Chemo Open Access. 2016;5: 205.
127. Panneerselvam J, et al. Fanconi Anemia Group D2 Protein Participates in Replication Origin Firing. Chemo Open Access. 2016;5:206.
128. Liu B, et al. Dihydromyricetin Induces Apoptosis by Reducing TGF- $\beta$  via P53 Activation in HepG2 Cells. Chemo Open Access. 2016;5:207.
129. Hassanen EM, et al. Comparative Study between Vinorelbine based Versus Taxanes based Chemotherapy in Treatment of Parenchymal Metastatic Breast Cancer. Chemo Open Access. 2016;5:208.
130. Xiang L and Liang H. Interleukin-12 Implication in Tumor Initiating Capacity of Colorectal Cancer Stem Cells. Chemo Open Access. 2016;5:209.
131. Mori R, et al. Effective Hormone Therapy Reduces the Efficacy of Subsequent Chemotherapy in Hormone-Receptor-Positive Metastatic Breast Cancer. Chemo Open Access. 2016;5:210.
132. Chiang JM, et al. Real World Effectiveness of Different Postoperative Adjuvant Chemotherapy Regimens in Stage III Colon Cancer Patients. Chemo Open Access. 2016;5:211.
133. Radini IAM. A Multi-Component Reaction to 6-Aminothiouracils: Synthesis, Mechanistic Study and Antitumor Activity. Chemo Open Access. 2016;5:212.
134. Martin L, et al. RXDX-107, A Dodecanol Alkyl Ester of Bendamustine, Demonstrates Greater Stability and Broad Antitumor Activity in Multiple Pre-Clinical Models of Solid Tumor. Chemo Open Access. 2016;5:213.
135. Ghosh J and Bajpai J. Epithelial Ovarian Cancers: On-Target is Better than Near-Target. Chemo Open Access. 2016;5:214.
136. Filho RSO, et al. Main Barriers in Control of Energy-Protein Deficit in Critical Oncologic Patient at Nutritional Risk. J Integr Oncol. 2016;5:156.
137. Mastrangelo D, et al. The Cure from Nature: The Extraordinary Anticancer Properties of Ascorbate Vitamin C. J Integr Oncol. 2016;5:157.

138. Lai-Tiong F. Chemotherapy-Induced Nausea and Vomiting: An Oncology-Day Unit Experience. *J Integr Oncol.* 2016;5:158.
139. Mukherjee G, et al. Analysis of Clinico-Pathological Characteristics of Indian Breast Cancers Shows Conservation of Specific Features in the Hormone Receptor Sub-Types. *J Integr Oncol.* 2016;5:159.
140. Barreca S, et al. Huge Liposarcoma of the Forefoot: A Case Report. *J Integr Oncol.* 2016;5:160.
141. Giulio GM, et al. Local Resections and Prosthetic Reconstructions in Solitary Bone Metastases of the Limbs According to Histotypes. *J Integr Oncol.* 2016;5:161.
142. Couderc AL, et al. Prognostic Factors in Elderly Patients with Multiple Myeloma Treated with Weekly Bortezomib. *J Integr Oncol.* 2016;5:162.
143. Cheng Q, et al. Meta-analysis of CXCR7 Expression Related to Clinical Prognosis in Cancers. *J Integr Oncol.* 2016;5:163.
144. Qun W, et al. Effective Personalized Treatment of Advanced Hepatic Carcinoma based on Sorafenib. *J Integr Oncol.* 2016;5:164.
145. Nekkanti S, et al. An Unusual Presentation of Non Union of Patella with Full Range of Movements of the Knee Joint. *J Integr Oncol.* 2016;5:165.
146. Recchia F, et al. Long-term Follow-up of Pegylated Liposomal Doxorubicin and Oxaliplatin in Recurrent Ovarian Cancer. *J Integr Oncol.* 2016;5:166.
147. Ruzzenente A, et al. Risk A Novel Prognostic Score based on Serum Alpha-Fetoprotein, Number of Nodules, and MYC Gene Status Predicts Prognosis of Patients after Liver Resection for Hepatocellular Carcinoma. *J Integr Oncol.* 2016;5:168.
148. Hosiriluck N and Jones C. Emergence of Squamous Cell Carcinoma during Treatment of Basal Cell Carcinoma with Vismodegib. *J Integr Oncol.* 2016;5:169.
149. Elm'hadi C, et al. A Huge Malignant Peripheral Nerve Sheath Tumor Revealing Von Recklinghausen's Disease. *J Integr Oncol.* 2016;5:170.
150. Masuda H, et al. Expression of Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) in Human Renal Cell Carcinoma. *J Integr Oncol.* 2016;5:171.
151. Carr BI, et al. An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels. *J Integr Oncol.* 2016;5:172.
152. Maciej P, et al. Mandibular Reconstruction with Osteo-cutaneous Free Flaps in a Patient after Extensive Surgery Supported with 3D Printed Models. *J Integr Oncol.* 2016;5:177.
153. Eugeniu B, et al. Dynamic Changes of Molecular Markers during Natural History in Metastatic Melanoma: Ethical Issues and Lessons to Learn. *J Integr Oncol.* 2016;5:176.
154. Sultan A, et al. Treatment of Metastatic Colorectal Cancer in a Pregnant Woman with Lynch Syndrome- A Case Report. *J Integr Oncol.* 2016;5:175.
155. Chen YC, et al. Validation of Breast Cancer Survival Prediction Model with SEER Database. *J Integr Oncol.* 2016;5:174.
156. Heidari A. Linear and Non-Linear Quantitative Structure-Anti-Cancer-Activity Relationship (QSACAR) Study of Hydrated Ruthenium (IV) Oxide (RuO<sub>2</sub>) Nanoparticles as Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Anti-Cancer Nano Drugs. *J Integr Oncol.* 2016;5:e110.